Rate My Professor Carlos Salomon

Professor Carlos Salomon Gallo is a Professor at the University of Queensland Centre for Clinical Research, where he serves as group leader of the Exosome Biology Laboratory and NHMRC Investigator Fellow (EL2). He holds a Bachelor of Biochemistry and a Masters (Research) of Clinical Medicine from Universidad de Concepción, and a Doctor of Philosophy from Universidad de Chile. His research program has focused on obstetrics and gynaecology, investigating the release of extracellular vesicles by the placenta during gestation and by tumour cells in ovarian cancer progression, along with their utility as biomarkers for pregnancy complications and ovarian cancer. He is nationally and internationally recognised as a key opinion leader on extracellular vesicles, ranked third worldwide and first in Australia in expertise for extracellular vesicles and exosomes. In the past decade, his primary activities have centred on biomarker identification and validation, development of in vitro multivariate index assays for clinically relevant complications including ovarian cancers and obstetrical syndromes, and their translation into clinical applications. He has pursued these objectives through leadership of clinical translation research teams and facilities in Australia and overseas, including a leadership role in establishing the Centre for Clinical Diagnostics. Within the UQ Centre for Clinical Research, he established an exosome research team to evaluate the clinical utility of extracellular vesicles as liquid biopsies, in vitro diagnostics and therapeutics, applying ISO standards to isolation and characterisation methods including protein solution arrays, mass spectrometry profiling and miRNA analysis. His group explores the role of extracellular vesicles under normal and pathological conditions to assess their utility as disease biomarkers and therapeutic interventions. The major impact of his publications includes identifying new pathways for fetal-maternal and cancer communication, and establishing the clinical utility of endogenous nanovesicles as liquid biopsy biomarkers and therapeutic agents, providing a novel conceptual basis for changes in clinical practice and management.